On this week’s episode of "The Readout LOUD": Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s new trust-in-science reporter Nicholas Florko about the impact of Americans’ growing skepticism of science.  Your co-hosts also chat about a clinical update from UniQure on its gene therapy for Huntington’s disease, a juicy lawsuit filed by the gene-editing company Beam Therapeutics against a Chinese competitor, and a shift in the way pharma companies like Novo and Eli Lilly are talking about their GLP-1 products.

"The Readout LOUD" is going international this week. STAT's Jason Mast joins the podcast from Shanghai, where he's digging into what the rise of Chinese drug development means for the biotech industry. The hosts also speak to colleague Margaret Manto about Heidi Overton, the president's pick to be commissioner of the Food and Drug Administration. Will the new nominee bring some needed stability or controversy to the troubled agency? For more on Overton and her views on China, go here; to read about the ITM and Telix merger, go here; you can find the latest news on osteoporosis here.

International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We discuss that, plus the latest news in the life sciences, on this week's episode of "The Readout LOUD." STAT reporter Jonathan Wosen and Fanta Aw, the executive director of NAFSA: Association of International Educators, join the podcast to discuss a recent court decision around foreign visas for students. We also discuss the Definium's psychedelics data and what it means for that field as a whole. Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.

On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail? And what does this mean for the development of new heart medicines moving forward? Cardiologist and biotech entrepreneur Ethan Weiss joins us to discuss the surprising failures and long-term implications of two large clinical trials involving drugs developed from Novo Nordisk and Novartis, respectively. Plus, we have a recap of biotech news we missed while on hiatus, including a spurt of FDA drug approvals and the next big thing in cancer treatment from Merck and Moderna.

Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.It's a big week for FDA advisory committee meetings. Allison, Elaine, and Adam discuss Capricor Therapeutics' hearing in front of an FDA advisory committee. The company is asking the agency to approve its treatment for Duchenne, but advisers have questioned the data the company presented. They also discuss Replimmune's meeting with advisers to discuss its immunotherapy for melanoma.The hosts further discuss the latest news in the life sciences, including new details on how a fugitive worked as a biotech executive, cuts at GSK, and Sarepta Therapeutics' new CEO.

What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We speak with our colleagues Jason Mast and Matthew Herper about their impactful look at one father’s mission to develop a treatment for his daughter’s ultra-rare disease. The subject of that feature, Matt Wilsey, also joins us.

On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. Soon, you’ll be able to make bets on the outcomes of clinical trials and FDA drug reviews. Is that a good thing? We’ll discuss the issues with Jonathan Kimmelman, a bioethicist at McGill University who has researched prediction in clinical trials. We also chat about Biogen and its tau-lowering drug for Alzheimer’s. A mid-stage clinical trial presented this week showed the drug reduced levels of the tau protein and slowed the rate of cognitive decline in patients. But the data also raised a lot of questions that left experts and investors debating the drug’s future.

Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration commissioner? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. STAT reporter Bob Herman joins us to discuss his new series, "Out of Pocket, Out of Reach," which dives into how soaring costs for health insurance are hurting Americans and small business owners. We also speak with Chris Deacon, who filed a whistleblower lawsuit after spotting how an insurer may have violated contracts to provide health benefits for New Jersey's state workers. We also discuss the latest news in life sciences, including Anthropic's push into drug development and Vertex's largest-ever acquisition.

Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program. We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.